Obinutuzumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Obinutuzumab and local guidelines before prescribing.
Anti-CD20 antibody
Mechanism
Anti-CD20 monoclonal antibody.
Uses
CLL, follicular lymphoma.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Infusion reactions, tumour lysis syndrome, neutropenia, PML.
Interactions
Live vaccines contraindicated.
Contraindications and cautions
Active infection
Monitoring
FBC, U&E
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Tumour lysis prophylaxis; hepatitis B screen.
More from the textbook: uses, cautions and other points
- Venetoclax with obinutuzumab (fixed duration). Venetoclax carries a high tumour lysis syndrome risk - a slow dose ramp-up with hydration and monitoring.
Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia - Rituximab / obinutuzumab | Anti-CD20 antibodies; infusion reactions; hepatitis B reactivation (screen first); prolonged hypogammaglobulinaemia; rare PML.
Haematology: Myeloma and Lymphoma - Treat when there are symptoms, bulky disease, cytopenias, organ compromise or rapid progression: an anti-CD20 antibody (rituximab or obinutuzumab) with chemotherapy (bendamustine, CVP or CHOP), then anti-CD20 maintenance.
Haematology: Myeloma and Lymphoma